title: The systemic inflammatory response after spinal cord injury in the rat is decreased by α4β1 integrin blockade.
abstract: Abstract The systemic inflammatory response syndrome (SIRS) follows spinal cord injury (SCI) and causes damage to the lungs, kidney, and liver due to an influx of inflammatory cells from the circulation. After SCI in rats, the SIRS develops within 12 h and is sustained for at least 3 days. We have previously shown that blockade of CD11d/CD18 integrin reduces inflammation-driven secondary damage to the spinal cord. This treatment reduces the SIRS after SCI. In another study we found that blockade of α4β1 integrin limited secondary cord damage more effectively than blockade of CD11d/CD18. Therefore we considered it important to assess the effects of anti-α4β1 treatment on the SIRS in the lung, kidney, and liver after SCI. An anti-α4 antibody was given IV at 2 h after SCI at the fourth thoracic segment and the effects on the organs were evaluated at 24 h post-injury. The migration of neutrophils into the lungs and liver was markedly reduced and all three organs contained fewer macrophages. In the lungs and liver, the activation of the oxidative enzymes myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and gp91(phox), the production of free radicals, lipid peroxidation, and cell death were substantially and similarly reduced. Treatment effects were less robust in the kidney. Overall, the efficacy of the anti-α4β1 treatment did not differ greatly from that of the anti-CD11d antibody, although details of the results differed. The SIRS after SCI impedes recovery, and attenuation of the SIRS with an anti-integrin treatment is an important, clinically-relevant finding.
authors.affiliation: Spinal Cord Injury Team, Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
authors.forename: Feng
authors.initials: F
authors.lastname: Bao
authors.forename: Vanessa
authors.initials: V
authors.lastname: Omana
authors.forename: Arthur
authors.initials: A
authors.lastname: Brown
authors.forename: Lynne C
authors.initials: LC
authors.lastname: Weaver
mesh_terms: D000818:Animals; D039041:Integrin alpha4beta1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D020127:Recovery of Function / Q000187:drug effects; D013116:Spinal Cord / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D013119:Spinal Cord Injuries / Q000150:complications / Q000276:immunology / Q000378:metabolism*; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology / Q000276:immunology / Q000378:metabolism*
chemical_list: D039041:Integrin alpha4beta1